Table 3.

Association of SNPs in VEGFA, VEGFR1, VEGFR2, and KRAS genes with response to BCP therapy.

Gene	SNP	Alleles	RESPONSE TO TREATMENT
			Disease progression	Stable disease	Partial response	Complete response	p-value
VEGFR-1	rs9582036	CC	0 (0.0%)	6 (46.2%)	7 (53.9%)	0 (0.0%)	0.159
		AA	9 (14.3%)	29 (46.0%)	25 (39.7%)	0 (0.0%)
		AC	6 (8.7%)	21 (30.4%)	41 (59.4%)	1 (1.5%)
	rs7996030	GG	9 (11.3%)	32 (40.0%)	38 (47.5%)	1 (1.3%)	0.909
		AA	0 (0.0%)	1 (20.0%)	4 (80.0%)	0 (0.0%)
		AG	6 (10.0%)	23 (38.3%)	31 (51.7%)	0 (0.0%)
VEGFR-2	rs2071559	AA	0 (0.0%)	1 (20.0%)	4 (80.0%)	0 (0.0%)	0.909
		GG	9 (11.3%)	32 (40.0%)	38 (47.5%)	1 (1.3%)
		AG	6 (10.0%)	23 (38.3%)	31 (51.7%)	0 (0.0%)
	rs870377	AA	1 (16.7%)	3 (50.0%)	2 (33.3%)	0 (0.0%)	0.852
		TT	8 (8.9%)	34 (37.8%)	47 (52.2%)	1 (1.1%)
		AT	6 (12.2%)	19 (38.8%)	24 (49.0%)	0 (0.0%)
VEGF-A	rs3025039	CC	12 (11.8%)	37 (36.3%)	52 (51.0%)	1 (1.0%)	0.937
		TT	1 (5.3%)	9 (47.4%)	9 (47.4%)	0 (0.0%)
		CT	2 (8.3%)	10 (41.7%)	12 (50.0%)	0 (0.0%)
	rs833061	CC	3 (8.3%)	19 (52.8%)	14 (38.9%)	0 (0.0%)	0.036
		TT	3 (8.1%)	19 (51.4%)	15 (40.5%)	0 (0.0%)
		CT	9 (12.5%)	18 (25.0%)	44 (61.1%)	1 (1.4%)
	rs2010963	CC	0 (0.0%)	5 (50.0%)	5 (50.0%)	0 (0.0%)	0.565
		GG	8 (12.5%)	27 (42.2%)	28 (43.8%)	1 (1.6%)
		CG	7 (9.9%)	24 (33.8%)	40 (56.3%)	0 (0.0%)
KRAS	rs10842513	CC	13 (10.5%)	45 (36.3%)	65 (52.4%)	1 (0.8%)	0.328
		TT	0 (0.0%)	0 (0.0%)	2 (100.0%)	0 (0.0%)
		CT	2 (10.5%)	11 (57.9%)	6 (31.6%)	0 (0.0%)
	rs12813551	CC	1 (6.3%)	4 (25.0%)	11 (68.8%)	0 (0.0%)	0.168
		TT	4 (7.0%)	29 (50.9%)	24 (42.1%)	0 (0.0%)
		CT	10 (13.9%)	23 (31.9%)	38 (52.8%)	1 (1.4%)
	rs10505980	CC	5 (7.9%)	31 (49.2%)	27 (42.9%)	0 (0.0%)	0.216
		TT	1 (6.3%)	4 (25.0%)	11 (68.8%)	0 (0.0%)
		CT	9 (13.6%)	21 (31.8%)	35 (53.0%)	1 (1.5%)

P-values marked with bold indicate statistically significant p-values.